CML Diagnostic and Staging Criteria: Old vs. New
The 2025 ELN recommendations now align with the 2022 WHO classification, which fundamentally restructures CML as a biphasic disease (chronic phase and blast phase only), eliminating the traditional accelerated phase category and lowering the blast threshold for blast phase from ≥30% to ≥20%. 1
Diagnostic Criteria (Unchanged Core Elements)
The hallmark diagnostic requirement remains detection of the BCR::ABL1 fusion gene created by t(9;22) translocation (Philadelphia chromosome). At diagnosis, perform:
- Bone marrow morphology and conventional chromosome banding analysis (CBA)
- RT-PCR on peripheral blood or bone marrow to identify BCR::ABL1 transcript type
- These tests detect variant translocations, cryptic rearrangements, and additional chromosomal abnormalities (ACA) 1
Critical pitfall: Some commercial RT-PCR kits don't recognize rare transcripts (like e1a2/p190). If you get discrepant results (negative RT-PCR with positive cytogenetics), investigate further 1, 2
Old Staging System (Pre-2022 WHO)
The traditional triphasic classification used in clinical trials and 2020 ELN recommendations:
Chronic Phase (CP)
- <10% blasts in blood or marrow
- <20% basophils in blood
- Platelets >100 × 10⁹/L
- No extramedullary disease
Accelerated Phase (AP) - MD Anderson Criteria
- 10-19% blasts in blood or marrow
- ≥20% basophils in blood
- Platelets <100 × 10⁹/L unrelated to therapy
- Clonal evolution (ACA in Ph+ cells)
Blast Phase (BP)
- ≥30% blasts in blood or marrow
- Extramedullary blast proliferation
- Large clusters of blasts in bone marrow biopsy
New Staging System (2022 WHO/2025 ELN)
The accelerated phase has been eliminated. CML is now classified as:
Chronic Phase
- <20% blasts in blood or marrow
- Patients may have high-risk features (see below) but remain classified as CP
Blast Phase
- ≥20% blasts in blood or marrow (lowered from ≥30%)
- Extramedullary blast proliferation
- Large clusters of blasts in bone marrow biopsy
High-Risk Features in Chronic Phase
The new classification recognizes patients can present with concerning features without reclassifying them as advanced phase:
- Elevated blast percentage (10-19%)
- Thrombocytopenia (<100 × 10⁹/L)
- Basophilia (≥20%)
- High-risk ACA (major route: +8, +Ph, i(17q), +19, +17, +21; minor route: -7/7q-, 11q23, 3q26.2)
- Complex karyotypes
These features warrant closer monitoring and may influence treatment intensity but don't change phase classification 1
Rationale for the Change
The 2022 WHO revision was driven by several key observations:
Genomic studies show CML is biologically biphasic: Genetic changes characteristic of blast phase are present in what was called "accelerated phase" but absent in chronic phase, suggesting AP represents early blast transformation 1
Patients with 20-29% blasts behave more like those with ≥30% blasts than those with 10-19% blasts, supporting the lower threshold 1
Alignment with AML criteria: Since AML diagnosis changed from ≥30% to ≥20% blasts, CML blast phase needed similar alignment 1
Clinical practice reality: Most patients meeting old AP criteria at diagnosis respond to TKI therapy similarly to CP patients, making the distinction clinically less meaningful 1, 5
Practical Implications
For newly diagnosed patients: Approximately 6% previously classified as AP will now be classified as CP under 2022 WHO criteria 6. These patients typically receive standard TKI therapy with closer monitoring.
For treatment decisions: The blast percentage between 20-30% identifies patients who may benefit from more aggressive approaches including allogeneic stem cell transplantation when feasible 1
For emerging ACA during treatment: Additional chromosomal abnormalities appearing in Ph+ cells during therapy remain a warning sign of disease progression risk, regardless of classification system 1
Additional Diagnostic Considerations
- BCR::ABL1 mutation testing at diagnosis is NOT recommended in chronic phase (mutations are rare) 1
- Next-generation sequencing (NGS) IS recommended for patients presenting in or progressing to blast phase 1
- Somatic mutations in non-BCR::ABL1 genes occur in 20-30% of patients but have unclear therapeutic implications in chronic phase; testing remains a research tool 1
The controversy continues, as some experts argue the long-standing triphasic system remains clinically useful 1. However, the 2025 ELN recommendations have adopted the 2022 WHO biphasic classification as the new standard 1.